Active Filter(s):
Details:
This NIAID-funded project will assess the safety and efficacy of the Shigella bacteriophage preparation developed by Intralytix in Phase 1/2a clinical trials.
Lead Product(s): Shigella bacteriophage therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: NIAID
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 04, 2020